Search hospitals > Pennsylvania > Seneca
UPMC Cancer Center at UPMC Northwest
Claim this profileSeneca, Pennsylvania 16346
Global Leader in Skin Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Breast cancer
Conducts research for Stomach Cancer
98 reported clinical trials
21 medical researchers
Summary
UPMC Cancer Center at UPMC Northwest is a medical facility located in Seneca, Pennsylvania. This center is recognized for care of Skin Cancer, Lung Cancer, Breast Cancer, Breast cancer, Stomach Cancer and other specialties. UPMC Cancer Center at UPMC Northwest is involved with conducting 98 clinical trials across 241 conditions. There are 21 research doctors associated with this hospital, such as Liza C. Villaruz, Adam Brufsky, MD, Melissa A. Burgess, and Dan P. Zandberg.Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Liza C. VillaruzUniversity of Pittsburgh Cancer Institute (UPCI)6 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
40 reported clinical trials
59 drugs studied
Adam Brufsky, MDUniversity of Pittsburgh Cancer Institute (UPCI)1 year of reported clinical research
Expert in Breast Cancer
Expert in Breast cancer
31 reported clinical trials
70 drugs studied
Melissa A. BurgessUniversity of Pittsburgh Cancer Institute (UPCI)5 years of reported clinical research
Expert in Soft Tissue Sarcoma
Expert in Cancer
24 reported clinical trials
42 drugs studied
Dan P. ZandbergUniversity of Pittsburgh Cancer Institute (UPCI)4 years of reported clinical research
Expert in Skin Cancer
Expert in Squamous Cell Carcinoma
20 reported clinical trials
36 drugs studied
Clinical Trials running at UPMC Cancer Center at UPMC Northwest
Breast Cancer
Skin Cancer
Prostate Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Breast cancer
Bladder Cancer
Squamous Cell Carcinoma
Stomach Cancer
Oropharyngeal Carcinoma
Low Dose Tamoxifen
for Breast Cancer
This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy to treat postmenopausal women with hormone-dependent breast cancer. Giving low dose tamoxifen may be more effective compared to usual hormone therapy in treating post-menopausal women with hormone-positive, HER2 negative early stage breast cancer.
Recruiting2 awards Phase 38 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at UPMC Cancer Center at UPMC Northwest?
UPMC Cancer Center at UPMC Northwest is a medical facility located in Seneca, Pennsylvania. This center is recognized for care of Skin Cancer, Lung Cancer, Breast Cancer, Breast cancer, Stomach Cancer and other specialties. UPMC Cancer Center at UPMC Northwest is involved with conducting 98 clinical trials across 241 conditions. There are 21 research doctors associated with this hospital, such as Liza C. Villaruz, Adam Brufsky, MD, Melissa A. Burgess, and Dan P. Zandberg.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.